Article Sidebar

Download
PDF
Statistic
Read Counter : 0 Download : 0

Downloads

Download data is not yet available.

Main Article Content

Abstract

Introduction: Expanded dengue syndrome is a manifestation of dengue fever which involves various complications to other organs such as the brain, liver, kidneys, and heart.
Case presentation: A 32-year-old man was referred with altered mental status. He complained of fever, vomiting, headache and myalgia since two days before hospitalized for five days in previous hospital. On admission in our hospital he was delirium E2M5V2, normal other vital signs, and jaundice. Laboratory parameters showed Hb 15.9 g/dl, Ht 37%, WBC 26170/μl, platelet 16000/μl, creatinine 2.04 mg/dl, ureum 103 mg/dl, ALT 3711 U/l, AST 7961 U/l, total bilirubin 13.3 mg/dL, direct bilirubin 7.80 mg/dL, positive serum NS-1 antigen, anti-dengue IgM and IgG, while negative seromarkers for hepatitis A, B, and C, malaria and IgM Salmonella. The head CT scan examination was suggestive of cerebral edema. The abdominal ultrasound results was fatty liver. The patient was given 1 g daily of intravenous methyl prednisolone tapering off, curcuma xanthorrhiza, and intravenous stronger neo-minophagen C. The patient had good response and was discharged after 8 days of hospitalization.
Conclusion: This case report establishes expanded dengue syndrome with multiple organ involvement. Prompt diagnosis and treatment and elimination of differential diagnoses is crucial.

Keywords

liver encephalitis Expanded dengue syndrome

Article Details

References

  1. Aabiya Arif, Muhammad Raheel Abdul Razzaque, Lucas Marian Kogut, et al: Expanded dengue syndrome presented with rhabdomyolysis, compartment syndrome, and acute kidney injury. 2022;101(7): e28865. https://doi. org/10.1097/MD.0000000000028865
  2. Maheswaran Umakanth, Navaneethakrishnan Suganthan. Unusual Manifestations of Dengue Fever: A Review on Expanded Dengue Syndrome. 2020; 2(9):e10678. doi: 10.7759/cureus.10678.
  3. Libraty, DH, Young, PR, Pickering, D, et al. High circulating levels of the dengue virus nonstructural protein NS1 early in dengue illness correlate with the development of dengue hemorrhagic fever. J Infect Dis 2002;186:1165-1168
  4. Libraty, DH, Endy, TP, Houng, HS, et al. Differing influences of virus burden and immune activation on disease severity in secondary dengue-3 virus infections. J Infect Dis 2002;185:1213-1221
  5. Vaughn, DW, Green, S, Kalayanarooj, S, et al. Dengue viremia titer, antibody response pattern, and virus serotype correlate with disease severity. J Infect Dis 2000;181:2-9
  6. Peeling, RW, Artsob, H, Pelegrino, JL, et al. Evaluation of diagnostic tests: dengue. Nat Rev Microbiol 2010;8: Suppl:S30-S38
  7. Timothy J. Schaefer; Prasan K. Panda; Robert W. Wolford. Dengue Fever. StatPearls Publishing; 2024.
  8. World Health Organization. New Delhi: WHO; 2011. Comprehensive guidelines for prevention and control of dengue and dengue haemorrhagic fever. Revised and expanded edition.
  9. Maheswaran Umakanth, Navaneethakrishnan Suganthan. Unusual Manifestations of Dengue Fever: A Review on Expanded Dengue Syndrome. 2020; 2(9):e10678. doi: 10.7759/cureus.10678.
  10. Peeling, RW, Artsob, H, Pelegrino, JL, et al. Evaluation of diagnostic tests: dengue. Nat Rev Microbiol 2010;8: Suppl:S30-S38
  11. Cameron P. Simmons, Ph.D., Jeremy J. Farrar, M.D., Ph.D., Nguyen van Vinh Chau, M.D., Ph.D., and Bridget Wills, M.D., D.M. Dengue. N Engl J Med. 2012; 366:1423-1432. DOI:
  12. 1056/NEJMra1110265
  13. Tricou, V, Minh, NN, Farrar, J, Tran, HT, Simmons, CP. Kinetics of viremia and NS1 antigenemia are shaped by immune status and virus serotype in adults with dengue. PLoS Negl Trop Dis 2011;5:e1309-e1309
  14. Chaterji, S, Allen, JC Jr, Chow, A, Leo, YS, Ooi, EE. Evaluation of the NS1 rapid test and the WHO dengue classification schemes for use as bedside diagnosis of acute dengue fever in adults. Am J Trop Med Hyg 2011;84:224-228
  15. Dussart, P, Petit, L, Labeau, B, et al. Evaluation of two new commercial tests for the diagnosis of acute dengue virus infection using NS1 antigen detection in human serum. PLoS Negl Trop Dis 2008;2:e280- e280
  16. Hunsperger, EA, Yoksan, S, Buchy, P, et al. Evaluation of commercially available anti-dengue
  17. virus immunoglobulin M tests. Emerg Infect Dis 2009; 15:436-440
  18. Neurological complications of dengue infection. Murthy JM. Neurol India. 2010;58:581–584.
  19. Varatharaj A: Encephalitis in the clinical spectrum of dengue infection . Neurol India. 2010, 58:585-91. 10.4103/0028-3886.68655
  20. C. Soares, M. Puccioni-Sohler, Diagnosis criteria of dengue encephalitis, Arq Neuropsiquiatr 72 (3)
  21. (2014) 263, https://doi.org/10.1590/0004- 282X20130251.
  22. T.S. Jugpal, R. Dixit, A. Garg, S. Gupta, V. Jain, R. Patel, et al., Spectrum of findings on magnetic resonance imaging of the brain in patients with neurological manifestations of dengue fever, Radiol. Bras. 50 (5) (2017) 285–290,
  23. https://doi.org/10.1590/0100-3984.2016.0048.
  24. V. Hegde, Z. Aziz, S. Kumar, M. Bhat, C. Prasad,
  25. A.K. Gupta, et al., Dengue encephalitis with predominant cerebellar involvement: report of eight cases with MR and CT imaging features, Eur. Radiol. 25 (3) (2015 Mar) 719–725, https://doi. org/10.1007/s00330-014-3473-6.
  26. Trivedi S, Chakravarty A: Neurological complications of dengue fever . Curr Neurol Neurosci Rep. 2022, 22:515-29. 10.1007/s11910-022-01213-7
  27. Carod-Artal FJ: Neurological manifestations of dengue viral infection . Res Rep Trop Med. 2014, 5:95-104. 10.2147/RRTM.S55372
  28. Heldner MR, Aguiar de Sousa D, Field TS, Coutinho JM, Zuurbier SM: Editorial: cerebral venous thrombosis. Front Neurol. 2022, 13:1021547. 10.3389/fneur.2022.1021547
  29. Domingues RB, Kuster GW, Onuki-Castro FL, Souza VA, Levi JE, Pannuti CS: Involvement of the central nervous system in patients with dengue virus infection. J Neurol Sci. 2008, 267:36-40. 10.1016/j.jns.2007.09.040
  30. Aaron M. Cook, G. Morgan Jones. Guidelines, et al. for the Acute Treatment of Cerebral Edema in Neurocritical Care Patients. Neurocrit Care. 2020; 32(3): 647–666.doi: 10.1007/s12028-020-00959-7
  31. Lizarraga KJ, Nayer A. Dengue-associated kidney disease. J Nephropathol. 2014;3:57–62.
  32. Mohsin N, Mohamed E, Gaber M, et al. Acute tubular necrosis associated with non-hemorrhagic dengue fever: a case report. Ren Fail. 2009;31:736–739.
  33. Kuo MC, Lu PL, Chang JM, Lin MY, Tsai JJ, Chen YH, Chang K, Chen HC, Hwang SJ, 2008. Impact of renal failure on the outcome of dengue viral infection. Clin J Am Soc Nephrol 3: 1350–1356.
  34. Laoprasopwattana K, Pruekprasert P, Dissaneewate P, Geater A, Vachvanichsanong P, 2010. Outcome of dengue hemorrhagic fever-caused acute kidney injury in Thai children. J Pediatr 157: 303–309.
  35. Mallhi TH, Khan AH, Adnan AS, Sarriff A, Khan YH, Jummaat F, 2015. Incidence, characteristics and risk factors of acute kidney injury among dengue patients: a retrospective analysis. PLoS One 10: e0138465.
  36. Nair JJ, Bhat A, Prabhu MV, 2016. A clinical study of acute kidney injury in tropical acute febrile illness. J Clin Diagn Res 10: OC01–OC05.
  37. Mehta RL, Kellum JA, Shah SV, Molitoris BA, Ronco C, Warnock DG, Levin A, 2007. Acute Kidney Injury Network: report of an initiative to improve outcomes in acute kidney injury. Crit Care 11: R31.
  38. Ostermann M, Joannidis M, 2016. Acute kidney injury 2016: diagnosis and diagnostic workup. Crit Care 20: 299.
  39. Selby NM, Fluck RJ, Kolhe NV, Taal MW, 2016. International criteria for acute kidney injury: advantages and remaining challenges. PLoS Med 13: e1002122.
  40. Lima EQ, Nogueira ML. Viral hemorrhagic fever- induced acute kidney injury. Semin Nephrol 2008; 28: 409–415
  41. Pang T, Cardosa MJ, Guzman MG. Of cascades and perfect storms: the immunopathogenesis of dengue haemorrhagic fever-dengue shock syndrome (DHF/DSS). Immunol Cell Biol 2007; 85: 43–45
  42. Nascimento EJ, Hottz ED, Garcia-Bates TM, et al. Emerging concepts in dengue pathogenesis: interplay between plasmablasts, platelets, and complement in triggering vasculopathy. Crit Rev Immunol 2014; 34: 227–240
  43. João Fernando Picollo Oliveira, Emmanuel A. Burdmann. Dengue-associated acute kidney injury. Clin Kidney J. 2015; 8(6): 681–685. https://doi. org/10.1093/ckj/sfv106
  44. Glassock RJ. Immune complex-induced glomerular injury in viral diseases: an overview. Kidney Int Suppl 1991; 35: S5–S7
  45. Wills BA, Nguyen MD, Ha TL, et al. Comparison of three fluid solutions for resuscitation in dengue shock syndrome. N Engl J Med 2005; 353: 877–889
  46. Cynober LA (Ed.), Metabolic and therapeutic aspects of amino acids in clinical nutrition., CRC Press, Washington, D.C. (2004), pp. 557-576
  47. Kopple JD, Massry SG (Eds.), Nutritional management of renal disease. (2nd edition), Lippincott, Williams and Wilkins, Philadelphia (2004), pp. 241-249
  48. Giovanni Landoni, M.D, Fabrizio Monaco, M.D et al. A Randomized Trial of Intravenous Amino Acids for Kidney Protection. N Engl J Med. 2024;391:687-698. https://doi. org/10.1056/NEJMoa2403769.
  49. Marianneau P, Steffan AM, Royer C, Drouet MT, Jaeck D, Kirn A, Deubel V. Infection of primary cultures of human Kupffer cells by Dengue virus: no viral progeny synthesis, but cytokine production is evident. JV irol. 1999;73:5201–5206.
  50. Thongtan T, Panyim S, Smith DR. Apoptosis in dengue virus infected liver cell lines HepG2 and Hep3B. J Med Virol. 2004;72:436–444.
  51. Seneviratne SL, Malavige GN, de Silva HJ. Pathogenesis of liver involvement during dengue viral infections. Trans R Soc Trop Med Hyg. 2006;100:608–614.
  52. Couvelard A, Marianneau P, Bedel C, Drouet MT, Vachon F, Hénin D, Deubel V. Report of a fatal case of dengue infection with hepatitis: demonstration of dengue antigens in hepatocytes and liver apoptosis. Hum Pathol. 1999;30:1106–1110.
  53. Huerre MR, Lan NT, Marianneau P, Hue NB, Khun H, Hung NT, Khen NT, Drouet MT, Huong VT, Ha DQ, et al. Liver histopathology and biological correlates in five cases of fatal dengue fever in Vietnamese children. Virchows Arch. 2001;438:107–115.
  54. Thongtan T, Panyim S, Smith DR. Apoptosis in dengue virus infected liver cell lines HepG2 and Hep3B. J Med Virol. 2004;72:436–444.
  55. Bhamarapravati N. Hemostatic defects in dengue hemorrhagic fever. Rev Infect Dis. 1989;11 Suppl 4:S826–S829.
  56. Burke T. Dengue haemorrhagic fever: a pathological study. Trans R Soc Trop Med Hyg. 1968;62:682– 692.
  57. Haan D. Therapie Compendium, Vierde Druk, D.,B. Amsterdam, Netherlands: Centen’s Uitgevers- Maatschappij N.V.; 1949.
  58. Heyne K. Tumbuhan Berguna Indonesia: Jilid I, Translated by Badan Litbang Kehutanan. Jakarta Pusat: Koperasi Karyawan Departemen Kehutanan; 1987.
  59. Adila R., Nurmiati, Agustien A. Uji antimikroba curcuma spp. terhadap pertumbuhan Candida albicans, Staphylococcus aureus, dan Escherichia coli. Journal Biologi University of Andalas. 2013;2(1):1–7.
  60. Susila K. A., Tellu A. T., Tangge L. Jenis dan pemanfaatan tanaman obat di Desa Tinading dan pengembangannya sebagai media pembelajaran. Journal Ilmiah Pendidikan Biologi. 2017;5(2):60– 70.
  61. Sudarsi E. Serat Primbon Djampi-Djampi Djawi. Mannheim, Germany: Wissenschaftsverlag; 1993.
  62. Salea R., Widjojokusumo E., Veriansyah B., Tjandrawinata R. R. Optimizing oil and xanthorrhizol extraction from Curcuma xanthorrhiza Roxb. rhizome by supercritical carbon dioxide. Journal of Food Science and Technology. 2014;51(9): 2197–2203. https://doi. org/10.1007/s13197-014-1272-3.
  63. Ozaki Y. Antiinflammatory effect of Curcuma xanthorrhiza Roxb. and its active principles. Chemical and Pharmaceutical Bulletin. 1990;38(4):1045–1048. doi: 10.1248/cpb.38.1045.
  64. Hwang J. K., Shim J. S., Pyun Y. R. Antibacterial activity of xanthorrhizol from Curcuma xanthorrhiza against oral pathogens. Fitoterapia. 2000;71(200):321–323.
  65. Lin S.-C., Teng C.-W., Lin C.-C., Lin Y.-H.,
  66. Supriyatna S. Protective and therapeutic effect of the Indonesian medicinal HerbCurcuma xanthorrhizaon β-D-Galactosamine-induced liver damage. Phytotherapy Research. 1996;10(2):131–
  67. doi: 10.1002/(sici)1099-
  68. (199603)10:2<131::aid-ptr786>3.0.co;2-0
  69. Masuda T., Isobe J., Jitoe A., Nakatani N. Antioxidative curcuminoids from rhizomes of Curcuma xanthorrhiza. Phytochemistry. 1992;31(10):3645–3647. doi: 10.1016/0031-
  70. (92)83748-n.
  71. Lim C. S., Jin D.-Q., Mok H., et al. Antioxidant and antiinflammatory activities of xanthorrhizol in hippocampal neurons and primary cultured microglia. Journal of Neuroscience Research. 2005;82(6):831–838. doi: 10.1002/jnr.20692.
  72. Kim S. H., Hong K. O., Hwang J. K., Park K.-K. Xanthorrhizol has a potential to attenuate the high dose cisplatin-induced nephrotoxicity in mice. Food and Chemical Toxicology. 2005;43(1):117–122. doi: 10.1016/j.fct.2004.08.018.
  73. Park J. H., Park K. K., Kim M. J., Hwang J. K., Park
  74. S. K., Chung W. Y. Cancer chemoprotective effects of Curcuma xanthorrhiza. Phytotherapy Research. 2008;22(5):695–698. doi: 10.1002/ptr.2418.
  75. Ruslay S., Abas F., Shaari K., et al. Characterization of the components present in the active fractions of health gingers (Curcuma xanthorrhiza and Zingiber zerumbet) by HPLC-DAD-ESIMS. Food Chemistry. 2007;104(3):1183–1191. doi: 10.1016/j.foodchem.2007.01.067
  76. Yasni S., Imaizumi K., Sin K., Sugano M., Nonaka G., Sidik Identification of an active principle in essential oils and hexane-soluble fractions of Curcuma xanthorrhiza Roxb. Showing triglyceride- lowering action in rats. Food and Chemical Toxicology. 1994;32(3):273–278. doi: 10.1016/0278-6915(94)90200-3.
  77. Michaelis M, Geiler J, Naczk P, Sithisarn P, Leutz A, Doerr HW, Cinatl J., Jr Glycyrrhizin exerts antioxidative effects in H5N1 influenza A virus- infected cells and inhibits virus replication and pro-
  78. inflammatory gene expression. PLoS One. 2011;6:e19705.
  79. Orlent H, Hansen BE, Willems M, Brouwer JT, Huber R, Kullak-Ublick GA, Gerken G, Zeuzem S, Nevens F, Tielemans WC, Zondervan PE, Lagging M, Westin J, Schalm SW. Biochemical and histological effects of 26 weeks of glycyrrhizin treatment in chronic hepatitis C: a randomized phase II trial. J Hepatol. 2006;45:539–546.
  80. Kumada H. Long-term treatment of chronic hepatitis C with glycyrrhizin [stronger neo-minophagen C (SNMC) for preventing liver cirrhosis and hepatocellular carcinoma. Oncology. 2002;62(Suppl 1):94–100.
  81. Arase Y, Ikeda K, Murashima N, Chayama K, Tsubota A, Koida I, Suzuki Y, Saitoh S, Kobayashi M, Kumada H. The long term efficacy of glycyrrhizin in chronic hepatitis C patients. Cancer. 1997;79:1494–1500.
  82. Akira Okada , Hayato Yamana et al. Effect of Branched-Chain Amino Acid Infusion on In- Hospital Mortality of Patients With Hepatic Encephalopathy and End-Stage Kidney Disease: A Retrospective Cohort Study Using a National Inpatient Database. 2022; 32(4):432-440. doi: 10.1053/j.jrn.2021.05.008.